SMAD4 and colorectal carcinoma: Thus, our study validates and further elucidates the molecular link between Smad4 loss and p53 loss, Wnt/β‐catenin activation, and intestinal carcinogenesis, providing novel, clinically relevant insights into the SMAD4 and TP53 mutations in CRC.